Suspension of trading

Spexis AG Stock Swiss Exchange

Equities

POLN

CH0106213793

Pharmaceuticals

Market Closed - Swiss Exchange 12:36:37 2025-03-19 pm EDT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 2022-03-30
Director of Finance/CFO - 2024-07-31
Director TitleAgeSince
Chairman 70 2019-11-19
Director/Board Member 65 2013-05-31
Director/Board Member 80 2021-12-29
Change 5d. change 1-year change 3-years change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
-0.11%-1.85%+9.57%-0.87% 76.53B
-1.19%-0.56%+38.21%+218.77% 54.36B
-2.03%+59.20%+59.20%+59.20% 49.13B
-0.01%-3.58%-43.25%-50.21% 47.49B
-1.81%-1.80%+29.70%-29.78% 26.64B
-1.55%+0.08%+53.24%-64.46% 20.76B
+0.55%-3.54%+36.67%+26.46% 18.42B
-1.10%-2.94%+105.73%+106.25% 17.92B
-1.69%-1.01%+30.17%+56.90% 13.66B
Average -0.99%-1.60%+23.03%+22.30% 36.1B
Weighted average by Cap. -0.88%-1.48%+26.29%+41.20%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW